However, considering the above-said, those anti-MIF SMDs that are not membrane-penetrable—thus specifically directed at extracellular -job 2- MIFs—overall appear preferable, although exceptions may apply to applications in cancer and stroke, in which intracellular MIF has been suggested to exert detrimental effects as well (125, 131). This evidence concerns the gene MIF and stroke disorder.